Skip to main content

Day: March 28, 2023

Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics

New York, NY, Alpharetta, GA, Tel Aviv, ISRAEL and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has entered into a letter of intent with Acumen Diagnostics Pte Ltd of Singapore for its CLIA/CAP-certified clinical testing lab Provista Diagnostics to license the laboratory developed test (LDT) rights to commercialize the sepsis PCR-based diagnostic test AcuSept® in the United States. AcuSept is a host (patient) immune response test that identifies 19 mRNA biomarkers of infection, sepsis and septic shock, and can be used to monitor patient response to treatment. Under the terms of the agreement, Provista will also conduct clinical validation studies on AcuSept® to generate the data in the United...

Continue reading

Upwork Appoints Erica Gessert as Chief Financial Officer

Gessert joins company from PayPal; will play pivotal role in next chapter of growth for the world’s largest work marketplace SAN FRANCISCO, March 28, 2023 (GLOBE NEWSWIRE) — Upwork Inc. (NASDAQ: UPWK), the world’s largest work marketplace that connects businesses with independent talent from across the globe, as measured by gross services volume (“GSV”), today announced that Erica Gessert will join the company as chief financial officer (CFO), effective April 25, 2023. Gessert joins from PayPal (NASDAQ: PYPL), where she held a number of senior leadership roles since 2015, most recently including chief transformation officer reporting to the CEO, and senior vice president of finance & analytics. “We are thrilled to welcome Erica to Upwork and look forward to benefiting from her decades of leadership experience across finance,...

Continue reading

Aware brings AwareID® to AWS Marketplace

By Leveraging AWS Marketplace’s Reach and with SoftwareONE’s help, Aware Will Further Expand Access to World Class Biometric Authentication Capabilities for Enterprise Customers Globally BURLINGTON, Mass., March 28, 2023 (GLOBE NEWSWIRE) — A vast majority of enterprises worldwide use cloud computing or applications based in the cloud, and this number is only set to grow in the coming years. In this context, AWS Marketplace is transforming how enterprises find, subscribe to and deploy third-party software, with decision-makers reporting feeling 2.4 times better about purchasing through AWS Marketplace compared to other sources. To tap this vast market reach and trust level, Aware, Inc. (NASDAQ: AWRE) announced it is working with SoftwareONE and AWS to prepare AwareID® for availability on AWS Marketplace. “AwareID will be one...

Continue reading

Savosolar Plc – Managers’ Transaction, Eero Auranne, March 2023

Savosolar Plc Company Announcement             28 March 2023 at 3.00 p.m. (CEST)Savosolar Plc – Managers’ Transaction, Eero Auranne, March 2023   Person subject to the notification requirementName: Auranne, Eero  Position: Member of the Board/Deputy member     Initial Notification  Reference number: 28036/5/4     IssuerName: Savosolar OyjLEI: 743700J1YZ8IEJAPDL21     Transaction detailsTransaction date: 2023-03-27Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)  Nature of the transaction:   Subscription Instrument: ShareISIN: FI4000425848   Volume: 6428Unit price: 0.05400 Euro Aggregated transactionsVolume: 6428Volume weighted average price: 0.05400 EuroSAVOSOLAR PLC For more information: Savosolar Plc Managing Director Jari Varjotie Phone: +358 400 419 734...

Continue reading

Distoken Acquisition Corporation Announces Upcoming Automatic Unit Separation, Commencing March 30, 2023

New York, NY, March 28, 2023 (GLOBE NEWSWIRE) — Distoken Acquisition Corporation (NASDAQ: DISTU) (the “Company”) announced today that, commencing March 30, 2023, the Company’s units will no longer trade, and that the Company’s ordinary shares, rights and warrants, which together comprise the units sold in the Company’s initial public offering, will commence trading separately. The ordinary shares, rights and warrants that are separated will trade on the Nasdaq Global Market under the symbols “DIST,”  “DISTR,” and “DISTW,” respectively. This is a mandatory and automatic separation, and no action is required by the holders of units. The units were initially offered by the Company in an underwritten offering. I-Bankers Securities, Inc. and IB Capital LLC acted as the joint book-runners for the offering. The offering was made only...

Continue reading

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

WATERTOWN, Mass., March 28, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the fourth quarter and full year ended December 31, 2022 and reviewed business highlights. “The mission of Acrivon is to pioneer a new era of precision oncology, and 2022 was an important year for us,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. “Amongst our many achievements, we are particularly excited about our successful IPO on NASDAQ and the...

Continue reading

RocketLinks participates in the international development of the Dékuple Group by expanding into the UK and US markets

Bertrand-Laurioz Dékuple CEO Bertrand-Laurioz Dékuple CEOMaxime Doki-Thonon Founder and CEO RocketLinks Maxime Doki-Thonon Founder and CEO RocketLinksRocketLinks participates in the international development of the Dékuple Group by expanding into the UK and US markets Paris, March 28, 2023 – RocketLinks, the Dékuple Group’s SaaS martech solution, continues its international development by expanding its market to the UK and the USA and is part of the Group’s overall internationalization process. With 10% of its revenue to be generated internationally by 2022, RocketLinks, a sponsored article buying platform that offers a full range of services for SEO and branding performance, has been preparing this expansion phase to international markets for several months:Recruitment of a business developer and a lead media...

Continue reading

Azincourt Energy Completes the 2023 Drill Program at the East Preston Uranium Project, Athabasca Basin, Saskatchewan

Vancouver, BC, March 28, 2023 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd.’s (TSX-V:SYH) (OTCQX:SYHBF) (Frankfurt:SC1P) (the “Company”) partner company Azincourt Energy (“Azincourt”) is pleased to announce that the 2023 exploration program has been completed at the East Preston uranium project in the Athabasca Basin, Saskatchewan, Canada. Project Location – Western Athabasca Basin, Saskatchewan, Canada:https://www.skyharbourltd.com/_resources/maps/Sky_EastPreston_20211209.jpg Drilling for the 2023 program at the East Preston Project commenced on February 2nd and was recently completed. In total 3,066 metres has been completed in 13 drill holes. After some initial startup delays due to extreme weather variations, two drill rigs were able to complete 12 drill holes and one abandoned due to drilling difficulties. Drilling was focused...

Continue reading

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Cantor Fitzgerald Future of Oncology Symposium, which is taking place virtually on April 3 – 5, 2023. Presentation details: Date: Tuesday, April 4 Time: 8:15 AM ET About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple...

Continue reading

Smart for Life’s Greens First CEO Ryan Benson Provides Video Update on Boxout Distribution Agreement

Video Details Transaction and Value of Agreement MIAMI, March 28, 2023 (GLOBE NEWSWIRE) — Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leader in the Health & Wellness sector marketing and manufacturing nutritional supplements and foods worldwide, today provided a video presentation of Ryan Benson, Greens First CEO, discussing the recently announced Boxout distribution agreement. Darren Minton, Chief Executive Officer of Smart for Life, noted, “The recently announced Boxout agreement entered into by Smart for Life’s Greens First subsidiary is a material event for us and a major component driving the growth of that company. Ryan Benson, Greens First CEO and a key member of our management team, engineered that transaction and the video presented here details the Boxout and Greens First partnership.” Interested...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.